LLY

#11
Eli Lilly and Company Common Stock
1074.1 0 USD
-2.83%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1 073.01
1 076.49
Intervallo Annuale
644.51
1 149.10
Variazione giornaliera
-2.83%
Variazione Mensile
+12.08%
Variazione di 6 mesi
+2.02%
Variazione Annuale
+46.20%
Chiusura Precedente
1105.3 7
Open
1075.0 2
Minimo
1073.0 1
High
1076.4 9
Volume
150
Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche Dividendi
Trimestrale Annuale
  • Market Capitalization 1.01 T
  • Employee 50 K
  • Founded N/A
  • CEO David A. Ricks
  • Website www.lilly.com
  • Headquarter Indiana, United States
  • FIGI BBG000BNBDC2
  • Industry Case Farmaceutiche - Generali
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
32.67
Rapporto prezzo/fatturato
11.44
Dividendi per azione
—
Rendimento da dividendi %
—

Eli Lilly and Company Common Stock

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes.

Notizie